Comparison of the Activities of Zanamivir, Oseltamivir, and RWJ-270201 against Clinical Isolates of Influenza Virus and Neuraminidase Inhibitor-Resistant Variants
暂无分享,去创建一个
[1] D. Smee,et al. In Vivo Influenza Virus-Inhibitory Effects of the Cyclopentane Neuraminidase Inhibitor RWJ-270201 , 2001, Antimicrobial Agents and Chemotherapy.
[2] W G Laver,et al. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. , 1998, Journal of medicinal chemistry.
[3] R. Webster,et al. How to overcome resistance of influenza A viruses against adamantane derivatives. , 1998, Antiviral research.
[4] P. Colman,et al. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor , 1992, Proteins.
[5] P. Ward,et al. Oral oseltamivir treatment of influenza in children , 2001, The Pediatric infectious disease journal.
[6] H. Jackson,et al. Oral Oseltamivir in Human Experimental Influenza B Infection , 1999, Antiviral therapy.
[7] R. Webster,et al. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. , 1998, The Journal of infectious diseases.
[8] D. Mendel,et al. Mechanism by Which Mutations at His274 Alter Sensitivity of Influenza A Virus N1 Neuraminidase to Oseltamivir Carboxylate and Zanamivir , 2002, Antimicrobial Agents and Chemotherapy.
[9] J. McKimm-Breschkin,et al. Resistance of influenza viruses to neuraminidase inhibitors--a review. , 2000, Antiviral research.
[10] P. Colman,et al. Mutations in a Conserved Residue in the Influenza Virus Neuraminidase Active Site Decreases Sensitivity to Neu5Ac2en-Derived Inhibitors , 1998, Journal of Virology.
[11] John J. Treanor,et al. Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza , 2000 .
[12] A. Osterhaus,et al. Zanamivir Susceptibility Monitoring and Characterization of Influenza Virus Clinical Isolates Obtained during Phase II Clinical Efficacy Studies , 2000, Antimicrobial Agents and Chemotherapy.
[13] D. Smee,et al. Cyclopentane Neuraminidase Inhibitors with Potent In Vitro Anti-Influenza Virus Activities , 2001, Antimicrobial Agents and Chemotherapy.
[14] R. Sidwell,et al. Characterization of Human Influenza Virus Variants Selected In Vitro in the Presence of the Neuraminidase Inhibitor GS 4071 , 1998, Antimicrobial Agents and Chemotherapy.
[15] A. Hay,et al. Structural characteristics of the M2 protein of influenza a viruses: Evidence that it forms a tetrameric channe , 1991, Virology.
[16] M. Lawrence,et al. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase , 1993, Journal of virology.
[17] M. Potier,et al. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. , 1979, Analytical biochemistry.
[18] A J Elliott,et al. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. , 2000, Journal of medicinal chemistry.
[19] J. Montgomery,et al. Comparison of the Anti-Influenza Virus Activity of RWJ-270201 with Those of Oseltamivir and Zanamivir , 2001, Antimicrobial Agents and Chemotherapy.
[20] N R Taylor,et al. Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B. , 1998, Journal of medicinal chemistry.
[21] R. Webster,et al. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en , 1997, Journal of virology.
[22] N. R. Taylor. Dihydropyrancarboxamides Related to Zanamivir: A New Series of Inhibitors of Influenza Virus Sialidases. Part 2. Crystallographic and Molecular Modeling Study of Complexes of 4-Amino-4H-pyran-6-carboxamides and Sialidase from Influenza Virus Types A and B. , 1998 .
[23] P. Colman,et al. Three‐dimensional structure of the complex of 4‐guanidino‐Neu5Ac2en and influenza virus neuraminidase , 1995, Protein science : a publication of the Protein Society.
[24] F. Hayden,et al. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. , 2001, The Journal of infectious diseases.
[25] P. Ward,et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. , 1999, JAMA.
[26] H. Jackson,et al. Management of Influenza , 2000 .
[27] Laurent Kaiser,et al. Influenza virus neuraminidase inhibitors , 2000, The Lancet.
[28] A. Monto,et al. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. , 2000, The New England journal of medicine.
[29] Paul W Smith,et al. Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. , 1998, Structure.